3E10-Hsp Fusion Proteins for Intracellular Protein Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are limited by the inability of cells to effectively transport large molecules such as proteins, necessitating the development of a method to deliver proteins into cells using molecular fusion proteins that exploit the hENT2 nucleoside salvage pathway.
Innovation Solution
The use of a cell-penetrating antibody, mAb 3E10, as a fragment or single chain variable fragment (3E10 scFv) fused with heat shock proteins (Hsp) or glucose regulated proteins (GRP78) to transport proteins into cells via the hENT2 nucleoside salvage pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If cells are treated with large molecules such as proteins, then therapeutic effects cannot be achieved, but using small molecules limits the range of treatable diseases
Solution Approach 1:
The patent combines a cell-penetrating antibody fragment (3E10 scFv) with heat shock proteins (Hsp70, Hsp27, Hsp90) or glucose-regulated proteins (GRP78) to create fusion proteins. This merging allows the large therapeutic protein molecules to be transported into cells by exploiting the hENT2 nucleoside salvage pathway, thereby achieving both the versatility of protein-based therapies and the cellular delivery reliability of small molecules.
2Ease of operation
If conventional therapy methods are used, then delivery into cells is not achieved, but developing new molecular fusion protein methods increases complexity
Solution Approach 1:
The patent uses the 3E10 scFv antibody fragment as an intermediary that mediates cellular uptake of the fused therapeutic proteins. The 3E10 scFv specifically binds to and exploits the hENT2 nucleoside salvage pathway on cell surfaces, acting as a delivery vehicle that simplifies the overall delivery process despite the complexity of the fusion protein structure.
3Reliability
If small molecules are used for therapy, then cellular delivery is achieved, but large molecule therapeutic options are lost
Solution Approach 1:
The patent changes the delivery parameter by exploiting the hENT2 nucleoside salvage pathway, which is normally used for small molecule nucleoside transport. By designing fusion proteins that utilize this existing pathway, the invention enables reliable cellular delivery of large protein molecules without requiring new delivery mechanisms, thus maintaining delivery reliability while expanding therapeutic molecule options.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method demonstrates the feasibility of transporting proteins into cells, providing a means to address diseases associated with hydrogen peroxide toxicity and reactive oxygen species (ROS) toxicity, including brain, heart, skin, and radiation injuries, as well as acute renal failure and cancer, through targeted intracellular delivery.
Implementation Method 1
mAb 3E10 is unique and distinguishable from other cell-penetrating peptides (CPPs) or protein transduction domains (PTDs) by its use of hENT2 nucleoside salvage pathway for entry into cells
Data Source
AI summary
The invention provides for a fusion protein comprising a 3E10 Fv joined to a Hsp-70, Hsp-27, Hsp-90 or GRP-78 or portion thereof, and optionally, the 3E10 Fv comprising an amino acid sequence AGIH at its amino terminus.